Back to results
US 2021/0263010 A1Published application
Ex vivo methods of screening for, and characterizing, cardiac therapeutics using preloaded cardiac tissues
AssigneeNovoHeart Limited
InventorsRonald A. Li, Kevin D. Costa
Life of this patent
Estimating the term…
Abstract
Provided are methods and materials for assaying known and candidate therapeutics for inotropic cardiac effects in one or more in vitro assay formats comprising preloaded cardiac tissues and/or organoids.
Claims42
A method of assessing the effect of a compound on a cardiomyocyte comprising:
- (a) preloading cardiomyocytes of a biocompatible gel apparatus by moving a biocompatible gel support member not fixed in space to stretch the biocompatible gel comprising cardiomyocytes, wherein the biocompatible gel apparatus comprises:
- (i) a biocompatible gel comprising a plurality of cardiomyocytes;
- (ii) a biocompatible support apparatus for suspending the biocompatible gel, wherein the biocompatible support apparatus comprises at least two support members, wherein a subset of the support members is fixed in space, and wherein the biocompatible gel and biocompatible support apparatus form a cardiac tissue strip comprising cardiomyocytes;
- (iii) a motor attached to at least one support member that is not fixed in space for stretching the biocompatible gel in at least one dimension;
- (iv) a detection device for detecting movement of the biocompatible gel;
- and
- (v) an electrical power source for applying an electrical pacing stimulus to the biocompatible gel;
- (b) administering an effective amount of a compound to the biocompatible gel;
- and
- (c) measuring the response of the biocompatible gel comprising cardiomyocytes to the compound.
7 more elements
A method for assaying a response of a cardiac organoid to a compound comprising:
- (a) preloading a cardiac organoid by adjusting the hydrostatic pressure to expand the cardiac organoid, wherein the cardiac organoid is housed in at least one organoid module comprising:
- (i) at least one organoid module, wherein each organoid module comprises a media inlet, a media outlet, and at least one wall compatible with an external detection device, wherein the cardiac organoid comprises at least one human cell, wherein the cell is a human embryonic stem cell, a human adult stem cell, a human induced pluripotent stem cell, a cell derived from a human tissue, or a progenitor cell of a human tissue, and wherein the cardiac organoid is in fluid communication with a fluid pump or a fluid reservoir comprising an adjustable volume of fluid, wherein the fluid pump or fluid reservoir modulates the pressure within the organoid;
- (ii) a mirror arrangement for simultaneous monitoring of any biological development of the cardiac organoid in each of at least two organoid modules;
- and
- (iii) a detection device for observing the monitored biological development of the cardiac organoid in each of at least two organoid modules;
- (b) administering the compound to the cardiac organoid;
- and
- (c) detecting a response of the cardiac organoid to the compound.
5 more elements
Dependencies are inferred from the claim text.